CRVS - コルバス・ファ―マシュ―ティカルズ (Corvus Pharmaceuticals Inc.) コルバス・ファ―マシュ―ティカルズ

 CRVSのチャート


 CRVSの企業情報

symbol CRVS
会社名 Corvus Pharmaceuticals Inc (コルバス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コーバス・ファーマスーティカル(Corvus Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は免疫腫瘍療法の開発と商品化に従事する。同社は免疫チェックポイントを阻止し、免疫T細胞を再プログラミングする薬物と抗体を開発する。同社は4つの免疫腫瘍学プログラムのパイプラインがあり、そのうち3つは免疫応答を調節するアデノシン - 癌軸に焦点を当てる。同社のリード製品候補であるCPI-444は免疫チェックポイントであるアデノシンに対するA2A受容体の経口・小分子アンタゴニストである。他の製品にはモノクローナル抗CD73抗体であるアデノシン産生阻害剤、アデノシンA2Bアンタゴニスト及びインターロイキン-2(IL-2)誘導性T細胞キナーゼ(ITK)阻害剤を含む。   コルバス・ファ―マシュ―ティカルズは米国の臨床段階のバイオ医薬品企業。がん治療のための新薬の開発・商品化に注力する。主に、アデノシンの生産を阻害及び抑制することで、免疫反応の調整を促す免疫腫瘍学のパイプラインを構築。また、T細胞の活性化と分化を調節するための治療薬も開発中。本社はカリフォルニア州。   Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
本社所在地 863 Mitten Road Suite 102 Burlingame CA 94010 USA
代表者氏名 Richard A. Miller リチャード・A・ミラー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 650-900-4520
設立年月日 41640
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 55人
url www.corvuspharma.com
nasdaq_url https://www.nasdaq.com/symbol/crvs
adr_tso
EBITDA EBITDA(百万ドル) -51.16600
終値(lastsale) 8.58
時価総額(marketcap) 250517613.06
時価総額 時価総額(百万ドル) 248.47380
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 115.24880
当期純利益 当期純利益(百万ドル) -50.57800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Corvus Pharmaceuticals Inc revenues was not reported. Net loss decreased 16% to $25.9M. Lower net loss reflects Research and development - Balancing val decrease of 18% to $20.3M (expense) General and administrative - Balancing decrease of 18% to $3.1M (expense) Interest income increase from $374K to $970K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.52 to -$1.03.

 CRVSのテクニカル分析


 CRVSのニュース

   Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results  2020/07/30 20:02:00 GlobeNewswire
Provides Update on CPI-006 Phase 1 COVID-19 Study Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., July 30, 2020 (GLOBE…
   The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy  2020/07/08 11:31:40 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) ( announced initiation of a Phase 1 study of a potential coronavirus treatment) Crispr Therapeutics AG (NASDAQ: CRSP ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Immunomedics, Inc.
   Corvus stock jumps on launch of early-stage trial for coronavirus treatment  2020/07/07 13:32:17 MarketWatch
Shares of Corvus Pharmaceuticals Inc. undefined soared 81.2% in trading on Tuesday after the company said it launched an open-label Phase 1 clinical trial…
   What Makes Corvus (CRVS) a New Buy Stock  2020/05/20 16:00:06 Zacks Investment Research
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Sign up as a Red Cross volunteer during coronavirus crisis  2020/03/26 16:34:42 Cornwall Live
So far more than 3,300 people across the region have joined the British Red Cross by signing-up to become community reserve volunteers (CRVs)
   Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results  2020/07/30 20:02:00 GlobeNewswire
Provides Update on CPI-006 Phase 1 COVID-19 Study Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., July 30, 2020 (GLOBE…
   The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy  2020/07/08 11:31:40 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) ( announced initiation of a Phase 1 study of a potential coronavirus treatment) Crispr Therapeutics AG (NASDAQ: CRSP ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Immunomedics, Inc.
   Corvus stock jumps on launch of early-stage trial for coronavirus treatment  2020/07/07 13:32:17 MarketWatch
Shares of Corvus Pharmaceuticals Inc. undefined soared 81.2% in trading on Tuesday after the company said it launched an open-label Phase 1 clinical trial…
   What Makes Corvus (CRVS) a New Buy Stock  2020/05/20 16:00:06 Zacks Investment Research
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Sign up as a Red Cross volunteer during coronavirus crisis  2020/03/26 16:34:42 Cornwall Live
So far more than 3,300 people across the region have joined the British Red Cross by signing-up to become community reserve volunteers (CRVs)
   The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy  2020/07/08 11:31:40 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) ( announced initiation of a Phase 1 study of a potential coronavirus treatment) Crispr Therapeutics AG (NASDAQ: CRSP ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Immunomedics, Inc.
   Corvus stock jumps on launch of early-stage trial for coronavirus treatment  2020/07/07 13:32:17 MarketWatch
Shares of Corvus Pharmaceuticals Inc. undefined soared 81.2% in trading on Tuesday after the company said it launched an open-label Phase 1 clinical trial…
   What Makes Corvus (CRVS) a New Buy Stock  2020/05/20 16:00:06 Zacks Investment Research
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Sign up as a Red Cross volunteer during coronavirus crisis  2020/03/26 16:34:42 Cornwall Live
So far more than 3,300 people across the region have joined the British Red Cross by signing-up to become community reserve volunteers (CRVs)
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コルバス・ファ―マシュ―ティカルズ CRVS Corvus Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)